Skip to main content
CVE-2022-38351VulnerabilityPublished Updated

CVE-2022-38351: n/a

Source CVE Database V5

0

Not known to be exploited · CVSS 8.8 High.

Data as of 25 Oct 2026, 19:02 UTC

CVSS 3.1 base score
8.8High
How severe the flaw is on the 0–10 CVSS scale.
EPSS
1.1% chance of exploitation in 30 days – higher than 65% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:3.1/AC:L/AV:N/A:H/C:H/I:H/PR:L/S:U/UI:N

Exploitation evidence

  1. Disclosed: evidence found.

    CVE published 19 Sep 2022

  2. Detectable: no evidence on record.

    No public nuclei template indexed

  3. Weaponised: no evidence on record.

    No public exploit code indexed in Metasploit or Exploit-DB

  4. Exploited in the wild: no evidence on record.

    Not in CISA KEV and no source reports exploitation

  5. Observed by OffSeq Mirage: no evidence on record.

    No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 2026-10-25.

What to do

Affected software

ProductAffectedFixed in
n/a n/aAffected
  • =2.8.16
Fixed in–

AI-suggested

To mitigate this vulnerability, European organizations should immediately verify if they are running Suprema BioStar 2 version 2.8.16 or earlier versions that might be affected. In the interim, organizations should restrict network access to the BioStar 2 management interface to trusted administrative networks only, using network segmentation and firewall rules to limit exposure. Implement strict monitoring and logging of access to the update profile page and related administrative functions to detect suspicious PUT requests or privilege escalation attempts. Employ multi-factor authentication for administrative accounts to reduce the risk of compromised credentials being leveraged. Conduct regular audits of user privileges and remove unnecessary low-privilege accounts that could be exploited. Additionally, consider deploying web application firewalls (WAFs) with custom rules to detect and block anomalous HTTP PUT requests targeting the update profile endpoint. Finally, ensure that incident response plans include procedures for rapid containment and remediation should exploitation be detected.

Description

A vulnerability in Suprema BioStar (aka Bio Star) 2 v2.8.16 allows attackers to escalate privileges to System Administrator via a crafted PUT request to the update profile page.

References

Community reviews

Loading reviews…